Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334232 | 0.81 | ALDH1A1 (0.50) | CYP2C19SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL8905685 | 0.81 | ALDH1A1 (0.50) | CYP2C19SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL13224056 | 0.81 | ALDH1A1 (0.50) | CYP2C19SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL8907259 | 0.80 | KCNA5 (0.44) | CYP2C19SMN1; SMN2ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL536277 | 0.79 | KDM4E (0.41) | CYP2C19SMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL10076563 | 0.79 | HTT (0.38) | CYP2C19SMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL536278 | 0.79 | KDM4E (0.41) | CYP2C19SMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL304924 | 0.79 | KDM4E (0.41) | CYP2C19SMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL8908400 | 0.79 | ALDH1A1 (0.44) | ALDH1A1GAACYP3A4 | |
| SCHEMBL888856 | 0.76 | CYP19A1 (0.36) | CYP2C19SMN1; SMN2HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP2C19 418/4885SMN1; SMN2 4162/4885HTT 4444/4885 |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP2C19 418/4885SMN1; SMN2 4162/4885HTT 4444/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP2C19 180/4885SMN1; SMN2 3741/4885HTT 4659/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP2C19 418/4885SMN1; SMN2 4162/4885HTT 4444/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CYP2C19 431/4885SMN1; SMN2 3298/4885HTT 4357/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CYP2C19 392/4885SMN1; SMN2 3515/4885HTT 4662/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CYP2C19 105/4885SMN1; SMN2 3511/4885HTT 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.